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Abstract Reimbursement agencies in several countries
now require health outcomes to be measured in terms of
quality-adjusted life-years (QALYs), leading to an immense
increase in publications reporting QALY gains. However,
there is a growing concern that the various ‘multi-attribute
utility’ (MAU) instruments designed to measure the Q in the
QALY yield disparate values, implying that results from
different instruments are incommensurable. By reviewing
cost-utility analyses published in 2010, we aim to contribute
to improved knowledge on how QALYs are currently cal-
culated in applied analyses; how transparently QALY mea-
surement is presented; and how large the expected
incremental QALY gains are. We searched Embase, MED-
LINE and NHS EED for all cost-utility analyses published in
2010. All analyses that had estimated QALYs gained from
health interventions were included. Of the 370 studies
included in this review, 48 % were pharmacoeconomic
evaluations. Active comparators were used in 71 % of stud-
ies. The median incremental QALY gain was 0.06, which
translates to 3 weeks in best imaginable health. The EQ-5D-
3L is the dominant instrument used. However, reporting of
how QALY gains are estimated is generally inadequate. In
55 % of the studies there was no reference to which MAU
instrument or direct valuation method QALY data came
from. The methods used for estimating expected QALY gains
are not transparently reported in published papers. Given the
wide variation in utility scores that different methodologies
may assign to an identical health state, it is important for
journal editors to require a more transparent way of reporting
the estimation of incremental QALY gains.
Key Points for Decision Makers
The incremental quality-adjusted life-year (QALY)
gains from medical technologies are generally small
Journal editors should require better transparency in
the reporting of how QALY gains have been
measured
The EQ-5D-3L is the most widely used instrument
for measuring health-related quality of life.
1 Introduction
Over the last 2 decades there has been an immense increase
in the number of published cost-utility analyses (CUAs, i.e.
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the type of cost-effectiveness analyses [CEAs] that mea-
sure health outcomes in terms of quality-adjusted life-years
[QALYs]). To illustrate this, we searched for CUAs in
Embase (Fig. 1), resulting in 37 hits from 1992, 425 from
2002 and 1,694 from 2012. This growing interest in
expressing outcomes in QALY terms may be explained by
a combination of research innovations and policy guide-
lines from reimbursement agencies [1].
Around 1980, some large-scale research projects started
developing multi-attribute utility (MAU) instruments
intended to measure health states on a scale of 0–1 [2]. The
motivation was to make health gains comparable across
symptoms and diagnoses. Much research effort was devo-
ted to constructing both generic descriptive systems and
valuation methods to assign values to the ‘health-related
quality of life’ (HRQoL, for short simply Q) associated
with being in various health states. The literature refers to
these numbers using different terms, such as ‘health utility
indices’, ‘quality of life values’, ‘utility values’, ‘health
state scores’ or simply QALY weights.
Principally, six MAU instruments have been developed
(EuroQoL-5 Dimensions [EQ-5D], Health Utilities Index
[HUI], Short-Form-6 Dimensions [SF6D], Assessment of
Quality of Life [AQoL], 15 Dimensions [15D], Quality of
Well-Being [QWB]), all based on different descriptive
systems and using different valuation methods. One major
challenge is evident in the literature that has compared the
alternative instruments: they yield different utility scores
for the same respondent for the same health state [3–5].
Such differences can be explained by descriptive systems
that cover different domains of health, and valuation
techniques (visual analogue scale [VAS], standard gamble
[SG], time trade-off [TTO], person trade-off [PTO]) that
produce different preference scores [6].
When different instruments produce different numbers
for the Q in the QALY formula, decision makers are faced
with incommensurable analyses. Government bodies in
some countries have therefore issued guidelines as to
which instrument should be applied in the estimation of
QALY gains. For instance in the UK, the National Institute
for Health and Care Excellence (NICE) recommends the
EQ-5D.
Methodological transparency becomes paramount to
make comparisons of study results. Interestingly, in their
key text on methods for economic evaluation, Drummond
et al. [7] provide a widely used checklist that includes
questions on whether outcomes were ‘measured accurately’
and ‘valued credibly’. An important motivation behind the
current review is to unravel the extent to which the esti-
mation of QALY gains in published CUAs was reported in
a transparent way. More specifically, the aim of this paper
is to examine three key questions: (i) How transparent is
the reporting of how QALYs are being estimated? (ii) How
is the Q in the QALY currently measured in published
CUAs? (iii) What is the size of the QALY gain reported?
The threshold value of the incremental cost-effective-
ness ratio (ICER), or society’s willingness to pay for a
QALY, has attracted much interest in the literature [8].
However, beyond the size of the ratio, there are many
reasons why the size of the denominator may have policy
relevance in its own right. Buyx et al. [9] recently pre-
sented the case for a ‘minimum effectiveness threshold’ of
3 months’ additional lifetime. Furthermore, there is an
increasing interest in the literature on assigning distributive
weights to QALYs, i.e. whether it is better to give large
gains to some few or small gains to the many [10]. In other
words, do people assign a constant marginal utility to
increasing QALY gains [11]? To bring some policy-rele-
vant context into this debate, it is worth knowing the size of
QALY gains in published analyses. In this context, it is
important to notice that QALY gains reported in CUAs
represent the average gain in the specified study
population.
2 Methodology
We searched the databases MEDLINE and Embase using
medical subject headings (MeSH) and Emtree terms and
text words related to economic evaluation and preference-
based QALY instruments. More specifically, we used the
MeSH and Emtree terms and text words to describe any
type of economic evaluation in combination with text
words for the six most frequently used MAU instruments
(EQ-5D, HUI, SF-6D, AQoL, 15D, QWB [2]) or the four
principal valuation methods (VAS, TTO, SG, PTO). For
convenience, the search was limited to the year 2010 and
thus provides a cross-sectional picture. Realizing that the
search may be missing some studies, we also searched the
Fig. 1 The growth of cost-utility analyses over the last 25 years
(search for cost-utility analysis in Embase)
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National Health Service Economic Evaluation Database
(NHS EED) for ‘cost-utility’.
Two reviewers read the abstracts and excluded studies
based on predefined criteria. The key inclusion criteria in
the review process were that papers should be published in
peer-reviewed English-language journals, and report from
an applied CUA, i.e. it should be an original health eco-
nomic evaluation with costs and QALYs as outcomes.
Studies were not excluded based on any data reported (or
not reported) in the results section; if an original CUA was
performed, the study was included.
Data were extracted from the studies to address the three
key questions of our objective:
1. How transparent is the reporting of how the QALY has
been measured?
2. How is the Q in the QALY currently measured in
published studies?
3. What is the size of the QALY gain in published
studies?
More specifically, we explore (i) which MAU instru-
ment was used (EQ-5D-3L, HUI, SF6D, AQoL, 15D,
QWB), (ii) on which valuation method (TTO, SG, VAS,
PTO) were health utility values based, (iii) what is the time
horizon over which the QALY gain is estimated?; and (iv)
which discount rates were used to time-adjust future health
benefits. Furthermore, we report the variation in the esti-
mated QALY gains, and look more closely into the studies
with the highest QALY gains to assess if these were due to
important medical breakthroughs.
To address these key issues, we provide some charac-
teristics of the published studies: the main type of disease,
country of origin, intervention type and type of journal.
These characteristics were hypothesized to possibly influ-
ence some of our key questions, such as methodological
transparency and size of QALY gain. For instance, it has
previously been found that articles published in journals
with low impact more often report favourable cost-effec-
tiveness results [12].
Most of the questions we posed could be answered by
providing frequency tables. In addition, we analyzed the
following differences with simple Chi-square tests:
1. Do health economic journals provide better reporting
of which MAU-instrument and valuation technique has
been applied?
2. Are large gains more common when the comparator is
placebo or no treatment?
3. Are large gains more common in any specific type of
journal?
All analyses were performed using SPSS (PASW Sta-
tistics 18).
3 Results
In total, 644 studies were identified. After exclusion of
studies that did not meet our inclusion criteria, data were
extracted from 370 studies (Fig. 2).
3.1 Characteristics of the Included Publications
Pharmaceuticals or not In total, 176 (47.6 %) studies dealt
with pharmacological interventions. The dominance of
pharmacoeconomic evaluations was expected, considering
that pharmaceutical companies in many countries are
obliged to submit a pharmacoeconomic evaluation as part
of a reimbursement application, while devices and proce-
dures in many jurisdictions still lack this kind of regulation.
Types of journals The journals in which the included
papers had been published were categorized into three
main types: (i) clinical or medical specialty journals, (ii)
non-specialty medical and health journals, and (iii) health
economics type journals (i.e. those with ‘economics’ or
‘technology assessment’ in their journal name, as well as
Social Science and Medicine and Value in Health). Only
24 % of the articles were published in this latter type of
journal (Table 1).
Country of origin Almost 70 % of the studies had their
origin in four countries: the USA (29 %), the UK (23 %),
Canada (8 %) and the Netherlands (8 %). The large pro-
portion of studies from the UK, Canada and the Nether-
lands might be explained by a combination of strong
involvement in developing MAU instruments as well as
policy guidelines that recommend the use of QALYs in
applications for reimbursements. Also, note that the only
health technology assessment (HTA) reports identified with
our search were from the UK, as these are indexed by
MEDLINE and Embase [13]. HTA agencies from other
countries may have published some of their analyses
through journal articles, but generally HTA reports are
disseminated in publications that are not found in searches
of regular databases [14].
Type of study Health economic evaluations can be per-
formed as part of an epidemiological study (most often a
415 studies evaluated in full text
229 references excluded
on the basis of title and abstract
45 studies excluded
4 not original CUA, 15 non-English, 
4 not QALY, 19 duplicates, 3 not CUA
370 studies included
644 identified references from
literature search
Fig. 2 Search diagram. CUA cost-utility analysis, QALY quality-
adjusted life-year
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randomized controlled trial [RCT]), as a modelling exer-
cise based on a synthesis of published data, or as a com-
bination of the two. Most studies included in this review
were models (80 %). The remainder were split equally
between the other two groups: strictly based on an RCT
with no modelling involved (10 %) or a combination of
RCT and modelling (10 %). The implication of this is that
a maximum of 20 % of the evaluations could have had
access to individual patient-level QALY data if these were
gathered in the RCT, while the rest, in general, would be
based on previously published data from one or more
sources.
Main disease group The disease groups targeted by the
interventions analyzed were categorized in eight groups:
cancer, cardiovascular diseases (CVDs), respiratory dis-
eases, mental health, other chronic diseases, non-chronic
diseases, lifestyle interventions and other prevention.
Clearly, the vast majority of studies focused on various
types of chronic diseases, with cancer and CVD being the
most frequent; 19 and 14 % of the studies, respectively.
Comparator With only 5 % placebo controlled and
24 % compared with a no-treatment situation, the vast
majority used an active comparator. However, it is
impossible to tell if the comparators were chosen to reflect
the most relevant alternative.
3.2 Measuring and Valuing Quality-Adjusted Life-
Year (QALY) Gains
In 205 studies (55 %), there was no reference to which
MAU instrument or direct valuation method formed the
basis for measuring ‘the Q in the QALY’ (Table 2).
However, most of these (147) papers had referred to other
publications from which they had obtained QALY data.
The remaining 58 were based on ‘mapping’ from a disease-
specific instrument, or the valuation method was not
specified at all.
Among the studies that explicitly referred to the use of
MAU instruments, the EQ-5D-3L was the most frequently
used: 87 of the 113 studies that were based on a single
instrument. In 11 studies, more than one MAU instrument
had been combined. The valuation method used for cal-
culating HRQoL was reported in only 85 (23 %) publica-
tions. TTO was the most widely used method, reflecting the
fact that most of these studies had applied the standard EQ-
5D-3L tariff from the UK, which is TTO based [15].
The combined information on which MAU instrument
and which valuation method had been applied was reported
in only 66 studies (18 %) (the 16 studies that stated direct
valuation and valuation method are included here). Either
MAU or valuation method was reported in 99 studies.
The combined information (which MAU instrument and
which valuation method) was reported in 29 % of publi-
cations in health economics journals, but in only 14 % of
medical journal publications (Table 3). Hence, reporting
was clearly better in health economics journals
(p = 0.0013).
3.3 The Size of QALY Gains
In 37 of the 370 studies included, the size of the incre-
mental QALY gain was not reported. Rather, these 37
studies reported the total QALY gain in the study group,
the probability that the intervention is cost effective or
simply the ICER.
Table 4 shows that the median incremental QALY gain
in the remaining 333 studies was 0.06, which translates to 3
Table 1 Descriptives of included studies (n = 370)
Descriptive n %
Intervention
Pharmaceutical 176 47.6
Not pharmaceutical 194 52.4
Journal type
Clinical/specialist 209 56.5
General (non-specialist) medical 72 19.5
Health economics type 89 24.1
Country of analysis
USA 106 28.6
UK 86 23.2
Canada 30 8.1
The Netherlands 29 7.8
Rest of the world 106 28.6
More than one country 13 3.5
Type of study
Model 297 80.3
Epidemiological study (35 RCTs) 37 10.0
RCT and model 36 9.7
Disease group
Cancer 71 19.2
Cardiovascular diseases 50 13.5
Respiratory diseases 22 5.9
Mental health 16 4.3
Other chronic diseases 130 35.1
Non-chronic diseases 41 11.1
Lifestyle interventions 18 4.9
Other prevention 22 5.9
Comparator
An active comparator 218 58.9
Several comparators 44 11.9
Placebo 20 5.4
No treatment 88 23.8
RCT randomized controlled trial
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weeks of prolonged life in best imaginable health (the
mean was 0.31 QALYs). The effect in the lowest quartile
translates to 4 days of prolonged life, while the upper
quartile was about 4 months or more. The generally low
QALY gains might be due to short time horizons over
which the gain had been measured and estimated. Table 4
shows that gains are increasing with time horizon, but not
much: the median QALY gain in studies with a time
horizon longer than 5 years was only 0.12.
When comparing QALY gains across diagnostic groups
(Table 5), we note that interventions related to other
chronic diseases yield the highest incremental gains while
preventions yield the lowest.
Given the generally low QALY gains in this review, we
looked closer into the 29 studies (8 %) that reported a gain
larger than 1 QALY. These large gains were most common
when the comparator was placebo or no-treatment (14 vs.
7 %, p = 0.03). A further characteristic of these studies
was that most of them were published in health economic
journals (15 vs. 6 %, p = 0.01), which indicates more
methodological transparency. Furthermore, a higher pro-
portion of these 29 studies were based on data from ‘rest of
the world’ (14 vs. 7 %, p = 0.05), i.e. all countries except
for those explicitly mentioned in Table 1.
Eight studies reported incremental gains of two QALYs
or more. None of these involved a ‘large medical break-
through’. Rather they were interventions targeted at rela-
tively young patient groups who will benefit from an
improved HRQoL over many years. Six of these eight
studies compared the gains with a no-treatment alternative.
3.4 Discounting QALY Gains
Discounting QALY gains was common: 276 (75 %)
reported results using a positive discount rate, while 58
(17 %) presented only the undiscounted result. In the
remaining 36 studies, the discounting issue was not
explicitly mentioned.
Table 2 Multi-attribute utility instrument and valuation method (n = 370)
Valuation method Total
TTO VAS/rating scales SG PTO Missing
Descriptive instrument
EQ-5D 31 11 0 0 45 87
SF-6D 0 1 3 0 9 13
HUI 0 0 0 0 6 6
15D 0 1 0 0 4 5
QWB 0 0 0 0 2 2
AQOL 0 0 0 0 0 0
More than one instrument 1 2 0 0 8 11
Mapping 2 3 2 0 35 42
Values from other cited publications 8 0 4 0 147 159
Direct valuation 11 1 3 1 6 22
Not specified 0 0 0 0 23 23
Total 53 19 12 1 285 370
AQOL assessment of Quality of Life, EQ-5D EuroQol-5 Dimensions, HUI Health Utility Index, PTO person trade-off, QWB Quality of Well-
Being, SF-6D Short Form-6 Dimensions, SG Standard Gamble, TTO time trade-off, VAS visual analogue scale, 15D 15 dimensions
Table 3 Details on utility method reported and journal type
Details on utility method reported Journal type Total
Health economics Clinical/specialist General
MAU and valuation 26 (29) 30 (14) 10 (14) 66 (17)
MAU or valuation 30 (34) 48 (23) 21 (29) 99 (37)
Not reported 33 (37) 131 (63) 41 (57) 205 (46)
Total 89 (100) 209 (100) 72 (100) 370 (100)
Data are presented as N (%)
MAU multi-attribute utility
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The most frequently applied discount rate was 3.0 %,
which has come to be the current standard rate in the lit-
erature, perhaps due to recommendations by the Wash-
ington panel [16]. Interestingly, studies that departed from
this international norm appeared to do so in response to
domestic guidelines. The Netherlands suggests a rate of
1.5 % in their guidelines, which explains why 17 of 27
studies using this rate have a Dutch setting. Similarly, the
UK guideline is 3.5 %, which explains why 52 of 62
studies using this rate are UK based.
When comparing the practice of discounting with time
horizon (Table 6), we note that most studies that did not
discount the gains, or contained no mention of discounting
(missing), were short-term studies (time horizon of 1 year
or less).
4 Discussion
4.1 Transparency
This review of 370 recently published CUAs shows that
most QALY calculations are not reported in a sufficiently
transparent way. The MAU instruments that were the basis
for estimating the Q in the QALY were reported in only
one-third of the published studies. In this journal’s check-
list for modelling studies, the question ‘‘Have you detailed
the methods that were used to obtain utility values?’’ is
obviously poorly answered, as only 19 % had reported the
combined information on which MAU instrument and
which valuation method were used.
In 43 % of the studies, references were provided for
readers and reviewers to search for original sources of
QALY weights themselves. We can only speculate as to
why such a large share of publications report references,
yet fail to follow guidelines that require the reporting of
which MAU instrument and which valuation method had
been applied. One possible reason for this lack of trans-
parency may be that authors hide facts regarding poor
QALY data, i.e. combination of different MAU instru-
ments, or references to other publications that are also
insufficient in their methodological reporting. Other rea-
sons may be that authors are unaware of guidelines for
publishing economic evaluations, or that they have read
Table 4 Quality-adjusted life-year gains vs. time horizon
Quartiles of QALY gain Time horizon levels
0.00–1.00 1.01–5.00 5.01–Lifetime Missing Total
(n = 62) (n = 55) (n = 190) (n = 26) (n = 333)
25th percentile 0.01 0.02 0.02 0.01 0.01
Median 0.02 0.08 0.12 0.07 0.06
75th percentile 0.04 0.24 0.47 0.45 0.32
Mean 0.04 0.17 0.43 0.36 0.31
QALY quality-adjusted life-year
Table 5 Quality-adjusted life-year gains vs. disease group
Quartiles of
QALY gain
Disease group
Cancer
(n = 63)
CVD
(n = 47)
Respiratory
(n = 21)
Mental
health
(n = 15)
Other chronic
diseases
(n = 120)
Non-chronic
diseases
(n = 32)
Lifestyle
interventions
(n = 16)
Other
prevention
(n = 19)
25th 0.02 0.01 0.00 0.03 0.02 0.01 0.01 0.00
Median 0.07 0.07 0.04 0.03 0.10 0.04 0.03 0.01
75th 0.33 0.32 0.25 0.20 0.56 0.28 0.15 0.03
CVD cardiovascular disease, QALY quality-adjusted life-year
Table 6 Discount rates and time horizon levels
Discount
rate
Time horizon levels
0.00–1.00 1.01–5.00 5.01–
Lifetime
Missing Total
0.0 42 (64) 5 (9) 7 (3) 4 (11) 58 (16)
1.5 1 (2) 9 (16) 16 (8) 1 (3) 27 (7)
3.0 1 (2) 19 (33) 118 (56) 19 (51) 157 (41)
3.5 4 (6) 13 (22) 41 (20) 4 (11) 62 (17)
4.0 1 (0.5) 1 (0.3)
5.0 2 (3) 6 (10) 17 (8) 4 (11) 29 (8)
Missing 16 (24) 6 (10) 9 (4) 5 (14) 36 (9)
Total 58 (100) 50 (100) 175 (100) 37 (100) 370 (100)
Data are presented as N (%)
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guidelines that are not sufficiently specific regarding the
reporting of MAU instrument and valuation method.
Recently published guidelines for reporting of health eco-
nomic evaluations [17] seem to be somewhat more explicit
on methodological transparency related to measuring QA-
LYs than the checklist provided in the most widely cited
text [7].
We expected that the incremental QALY gain, or at least
data from which this could be estimated, would be reported
in all publications. However, in 37 studies (10 %), we were
not able to find (or calculate) any incremental QALY gain.
These studies had either reported the total QALY gain in
the study group or the probability that the interventions
were cost effective. Clearly, to only report total QALY
gain does not comply with guidelines. To only report
probability of cost effectiveness is a limitation not
explicitly mentioned in most guidelines, but as pointed out
by Claxton et al. [18], ‘‘the intervention with the highest
probability of being cost-effective is not always the one
with the highest expected (i.e. mean) cost-effectiveness.’’
Hence, reporting only the probability of being cost effec-
tive is insufficient, unless the explicit goal is to prioritize
interventions according to probability of being cost effec-
tive, rather than according to cost effectiveness [19].
Our review shows that many published CUAs report
neither methods nor results as recommended in guidelines.
Although our review does not explicitly report on the same
breadth of information (or details) as, for example, the
Centre for Reviews and Dissemination database [20], our
findings suggest that everyone involved in the publication
process, i.e. authors, reviewers and editors, should adhere
to guidelines more strictly.
4.2 Describing and Valuing Health
Of the six MAU instruments, the high frequency of EQ-5D
use is in accordance with what others have found earlier,
both in reviews of published literature [21, 22] and in
reimbursement submissions [23]. The popularity of the
EQ-5D can be explained by many factors, one of which
might simply be its practicality. As the shortest instrument,
it occupies the least space in questionnaires that are likely
to already include a whole range of questions. However,
the wide use of an instrument is not necessarily an indicator
of quality. In an attempt to improve its quality, the
descriptive system has now been refined from three to five
levels (EQ-5D-5L).
Ten publications reported that two or more MAU
instruments had been used. More studies might also have
done so, while reporting the estimated incremental QALY
gains from only one instrument. The motivation for using
more than one instrument might be to increase the
probability of detecting an effect, as expressed in one
publication: ‘‘Of the two generic, preference-weighted,
health-related quality-of-life measures (standard gamble
preference-weighted SF-12 and QWB scale), the inter-
vention effect was only significant for the SF-12 QALY
and therefore only the SF-12 QALY results are pre-
sented.’’ [24]. Interestingly, the incremental QALY gain
reported in this particular study was only 0.018
(\1 week).
4.3 The Size of the Incremental Gain
The calculated QALY gains appear to be quite small,
which may indicate that large breakthroughs in health
science are rare. However, our review of reported QALY
gains indicates a wide variation in average expected gain
from interventions. When assessing sizes of QALY gains,
it is important to stress that these are mean values that do
not reveal how gains are distributed across patients. We
may have some idea based on the nature of the interven-
tions, i.e. a screening intervention would most likely have a
large benefit for the few that have a true positive test result
and give no benefit or even a negative benefit for the
healthy ones. For some chronic diseases, lifetime might not
be lengthened but the quality of life can be importantly
improved by new interventions or drugs.
More recently, some suggestions have been made about
introducing a minimum level of life extension in new
treatments to obtain public funding, or preferential public
funding. Based on a small German survey, Buyx et al. [9]
present the case for a ‘minimum effectiveness threshold’ of
3 months additional lifetime. Such a magnitude of gain
translates to an incremental QALY gain of 0.25, provided
that the increased lifetime involves ‘best imaginable
health’. In our review, only 30 % of published studies
showed gains with at least this magnitude. In the UK, the
same magnitude of life extension is required for classifi-
cation as ‘end-of-life treatments’, for which higher costs
per QALY will be accepted [25]. Here, an additional
requirement of a maximum of 2 remaining years of
expected lifetime should also be met.
4.4 Limitations of Our Review
Our review examined only CUAs published in 2010. This
may not be a representative sample, because some tech-
nologies might be over-represented if they were newly
introduced in that period or if there was a particular global
focus on a given disease.
When performing literature searches, there is most often
a trade-off between sensitivity and specificity: if you aim to
find all studies, you will have to read through thousands of
hits to be certain that none has slipped. In the present
article, we decided that specificity would be our priority.
Estimating QALY Gains in Applied Studies 373
In the articles where only references to sources of
QALY data were given, there is a potential for investi-
gating further in order to find more exact data. This is a
limitation of our paper with regards to the completeness of
the data. However, we believe that to comply with guide-
lines, and to be appropriately transparent, published papers
should report which MAU instrument and which valuation
method have been applied.
Given this very large sample of 370 published studies,
we had to concentrate on some limited topics: which MAU
instruments and valuations techniques were used, whether
the estimated gains were incremental to an active com-
parator, and the practice of discounting to adjust for dif-
ferential timing. There are certainly several other
methodological and normative issues to explore in future
reviews, e.g. to what degree utility values are based on the
preferences of the general public, patients’ experiences, or
healthcare personnel. However, this type of information is
rarely reported in CUAs, but has been reported in a sys-
tematic review of empirical studies [26] and a review of
pharmaceutical submissions [23].
5 Conclusions
Our review reveals a generally poor transparency in the
reporting of how incremental QALY gains are measured
and valued.
The EQ-5D-3L is the most widely used MAU instru-
ment, representing 77 % of those studies that reported
which instrument had been used.
The median of the incremental QALY gains reported in
370 CUAs from 2010 was 0.06.
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